Moderna Advances Bird Flu Vaccine Study, Reduces U.S. Operations

Moderna has announced it will continue its research into a potential vaccine for bird flu, though the company is limiting its U.S.-based operations as part of the effort. The move reflects a strategic shift to prioritize global health responses while maintaining essential studies in the United States.

The decision comes amid growing concerns over the spread of avian influenza, particularly the H5N1 strain, which has affected poultry and wild birds worldwide. Moderna’s vaccine development program remains active, with a focus on evaluating the safety and efficacy of its mRNA-based candidate.

In a statement, a Moderna spokesperson confirmed that the company is reducing in-person activities in the U.S. while continuing critical research remotely. The spokesperson emphasized that the company is committed to advancing its bird flu vaccine program and supporting global health authorities in their response efforts.

Key details of Moderna’s bird flu vaccine study:

• Study Phase: Early-stage clinical trials are ongoing to assess the vaccine’s safety and immunogenicity.
• Scope: The research includes both U.S.-based and international sites, with a reduced footprint in the U.S.
• Collaboration: Moderna is working with global health organizations to ensure its vaccine candidate can be rapidly deployed if needed.

Health experts have warned that avian influenza remains a significant public health risk, with sporadic cases of human infection reported in recent years. While the overall risk to the general population is considered low, health authorities are closely monitoring the situation.

Moderna’s decision to limit U.S. operations aligns with broader industry trends, as companies adapt to evolving public health priorities and regulatory landscapes. The company has not provided a timeline for when it expects to resume full-scale operations in the U.S.

For now, Moderna’s bird flu vaccine study continues, with a focus on advancing global health preparedness.